Chief Executive Officer
Dr. Jogin Desai is a general physician with extensive experience managing complex multinational teams and running global clinical research businesses. Dr. Desai joined Quintiles India in 2002 and held several positions of increasing responsibility, including heading the company's global ECG business. At that time, he was instrumental in building a highly successful global ECG business that grew from 20 staff members in 2002 to more than 250 staff members in Mumbai and Bangalore, India; Research Triangle Park, NC, USA; Bracknell, U.K.; and Tokyo, Japan. Prior to 2002, his last position in the United States was working in Abbott's clinical data management department. Dr. Desai holds a Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.), and also completed advanced management programs from INSEAD in Fontainebleau, France, and the Indian Institute of Management in Ahmedabad, India.
Senior Vice President, Operations
Sharad Gupta has been with Cenduit for more than four years and brings more than 30 years of experience to Cenduit. With more than 25 years of experience in the IT industry, Mr. Gupta began his career in sales and marketing and has worked with leading IT companies. Mr. Gupta was one of the main promoters of Amex Information Technologies (now Tutis Technologies) and led the company to a successful IPO in 1999. He has demonstrated strong leadership consistently throughout his career, most recently with the management of a distributed team to seamlessly integrate all operations of the acquisition of Webify Solutions by IBM India. Mr. Gupta earned a postgraduate degree in philosophy and has a diploma in marketing and sales.
Vice President, Finance
Mike Ederle served as CFO at Trinity Convergence, a multimedia and communications embedded software developer, from 2002 to 2010, overseeing all finance, accounting, legal, and IT operations. Additionally since 2008, Mr. Ederle served as co-CEO of the company. Prior to Trinity Convergence, Mr. Ederle was CFO and co-founder of Cerulic Inc., a Portland, Oregon-based start-up in the wireless data network arena. Mr. Ederle also served as CFO of PreNet Corporation, a start-up developing a next generation prepaid payment process for the wireless industry. He also served as vice president, finance, and administration, at eFusion, a VoIP applications company founded in 1996, where he was active in closing two private venture rounds totaling $26.6 million. Mr. Ederle has held financial management positions with Intel and Texas Instruments. He holds an MBA from the University of Washington and a Bachelor of Science in packaging engineering from Michigan State University.
Vice President, Quality Assurance
Jim Graffam joined Cenduit in 2008, complementing the organization with his more than 20 years' experience in quality management and operations across several industries and systems, including clinical trial software/services, real-time Doppler weather systems, retail point of sale systems, and telephony ordering interfaces. Mr. Graffam is responsible for maintaining Cenduit's quality framework, ensuring regulatory compliance, and the hosting and conducting of audits worldwide. Prior to his work at Cenduit, Mr. Graffam's experience included roles managing, testing, and deploying study-specific interactive response technology (IRT) solutions within the technical subsidiary of a major CRO. Mr. Graffam holds a Bachelor of Science degree in physics from Worcester Polytechnic Institute and a Master of Science degree in physics from Northeastern University.
Global Head of Human Resources
Lori Wilkinson is a human resources executive with more than 20 years of practical, field-tested experience in the private and public sectors. She has provided her expertise to early-stage and turnaround organizations in all areas of human resources, finance, and administration, specializing in the life sciences/biotechnology sector.
Ms. Wilkinson's professional experience includes key senior management positions with various start-up companies such as Oriel Therapeutics, TriVirix International, Serenex, Signature BioScience, and ACLARA BioSciences. While at each of these organizations, she successfully implemented a series of leadership development programs, various compensation and career path plans, change management programs, succession plans, integration teams, and communications programs.
She holds degrees from the University of California at San Francisco and the University of Akron and is a certified paralegal. She served on the board of BioSouth for its first three years and currently serves on the board of directors for two privately held start-up ventures.
Global Head of Technology
Chris brings over 15 years of experience architecting and delivering highly available, complex software applications across multiple industries including: health services, enterprise software, ecommerce, publishing, telecommunications, and consulting. Prior to joining Cenduit, Chris was the Chief Technology Officer of EmergingMed, a patient screening and recruitment service. He also served as the Vice President of Product Management at Luma Technologies, a provider of enterprise marketing communication software and as CTO for InfoGroup's expresscopy.com division, a leader in the e-commerce print marketing communication space. Chris holds a BS in Commerce from the University of Virginia and an MBA from the University of Maryland.
Senior Vice President and Head of Therapeutic Delivery Unit, Quintiles
Chris is an honors graduate of The Pennsylvania State University and the Duke University School of Medicine. He completed his Internship and Residency in Internal Medicine at Duke as well as a Chief Residency Year. He completed a Fellowship in Cardiology at Duke and completed a Masters in Health Sciences. He is Board Certified in both Internal Medicine and Cardiovascular Diseases.
Prior to joining Quintiles, Chris was on faculty at Duke University School of Medicine and the Duke Clinical Research Institute in Durham, NC where he was Director of the Echocardiography Core Lab, Associate Director of the ECG Core Laboratory, Co-Chair of the Cardiac Safety Research Consortium and Director of the International Collaboration on Endocarditis.
Chris began his career at Quintiles as the Cardiovascular / Endocrine Global Therapeutic Group Leader, providing medial advisor services and consulting expertise to cardiovascular projects, including cardiac safety and ECG projects including Thorough QT Studies. In addition, Chris managed a global team of 8 cardiovascular and endocrinology experts located throughout the world.
Chris went on to become the Chief Medical and Scientific Officer of Quintiles Transnational Corporation and the Cardiovascular/Endocrine Global Therapeutic Group Leader, where he was responsible for company-wide initiatives which focused on bioethics and the protection of human subjects. In addition, he was responsible for the development of initiatives that transformed the scientific strength of Quintiles into thought leadership positions and lead efforts that brought forward innovations in medicine, science, and technology into future business models. Finally, Chris was responsible for the Wellness Program and associated initiatives.
As the Senior Vice President of Global Access to Patients, Chris provided the visibility and focus needed to address the increasingly critical challenge of recruiting patients and developing a more efficient site infrastructure.
In his role as Senior Vice President and Head of the Therapeutic Delivery Unit, Chris incorporates Project Management, including Clinical Project Management with our Medical & Scientific Services group. This unit will be therapeutically organized with a strong customer focus to align our delivery with customers’ needs for therapeutic expertise in up-front planning/design and excellence in execution.
President, Fisher BioPharma Services
Patrick M. Durbin is President, Fisher BioPharma Services, a specialty division of Thermo Fisher Scientific. Durbin joined Thermo Fisher Scientific as General Manager, North America, for Fisher Clinical Services (FCS) in 2006 and was responsible for a suite of high-growth service lines that support the manufacturing, packaging, and distribution of drugs, biologics, and materials used in clinical trials. Durbin was promoted in 2008 to lead the Fisher Clinical Services business globally. Prior to joining FCS, Durbin had a 16-year career with Covance, formerly a division of Corning, where he held a variety of global senior management positions. He holds a bachelor's degree in biology and an MBA in pharmaceutical marketing. He has completed the General Management program at Columbia University and leadership development programs at both Thermo Fisher and Covance.
Senior Vice President, Quintiles Global IT
Eric Hodgins brings over 20+ years of global IT experience within the Life Sciences industry. Eric’s current role is Senior Vice President Quintiles Global IT with responsibility for Quintiles Infosario technology platforms and solutions. Eric’s background and areas of expertise include IT product management, systems development, offshoring models, solutions as a service, and P+L management. Before joining Quintiles, Eric was a cofounder of a successful life sciences IT startup. Eric has a Mechanical Engineering degree from the University of Texas at Austin.
Vice President and General Counsel, Customer Channels Group,
Thermo Fisher Scientific
John Sabo currently serves as Vice President and General Counsel of the Customer Channels Group of Thermo Fisher Scientific. In this role, he has responsibility for the legal, regulatory, and quality functions for Fisher Scientific, a $4 billion global business. Prior to joining Thermo Fisher Scientific, Sabo served in similar roles for several multinational companies, including Ariba, Marconi Communications, and Black Box Corporation. Sabo began his legal career with the law firm of Meyer, Unkovic & Scott, LLP, in Pittsburgh, where he was a member of the firm's business transactions and planning group. His practice focused on acquisitions and divestitures, private capital formation, joint ventures, contracts, and licensing. Sabo received his bachelor's degree in economics from Carnegie-Mellon University and his Juris Doctorate from Duquesne University.
Vice President Finance, Fisher BioPharma Services
Matthew P. Sudduth is Vice President Finance for the BioPharma Services Division of Thermo Fisher Scientific. Sudduth joined Thermo Fisher Scientific in 2006 and held various finance leadership roles in the Specialty Diagnostics Group before joining the BioPharma Services Division in 2010. In his current role, he is responsible for all financial aspects and strategic planning activities across the division's suite of high-growth service lines that support the manufacturing, packaging, and distribution of drugs, biologics, and materials used in clinical trials. Prior to joining Thermo Fisher Scientific, Sudduth was director of corporate finance at GenTek, a diversified chemical, telecommunications, and specialty automobile supply company. Prior to GenTek, he was a merchant banking associate with Latona Associates and an equity analyst with Mark Asset Management. Sudduth holds a bachelor's degree in philosophy from Bates College and an MBA from Columbia University.
Senior Vice President, Quintiles Global Laboratories and Cardiac Safety
Thomas Wollman is a Senior Vice President at Quintiles, managing the company's Global Laboratories and Cardiac Safety business units. Wollman joined Quintiles in 1996 upon the company's acquisition of BRI International, and went on to serve in a variety of finance roles before being named Global Head of Central Laboratories in 2005. He later took over leadership of Cardiac Safety in 2010.
In his current role, Wollman is responsible for managing the operations and strategy for the business units under his jurisdiction, including M&A strategic evaluation, execution, and integration. His focus is on leading with science-enhancing execution, driving scalability, and improving efficiency in these rapidly growing business units. In his tenure at Quintiles, Wollman has led the laboratory business through tremendous growth, spearheading the company's 2008 acquisition of TMD, 2011 acquisition of Advion Bioservices, and 2012 acquisition of Expression Analysis. His team includes more than 1,500 employees across 13 global locations, who perform a variety of services including biomarkers and esoteric evaluations.
Prior to joining Quintiles, Wollman served in a number of finance roles, including Chief Financial Officer of two publicly traded companies, Hadron, Inc. (now a part of QnetiQ as the result of several transactions) and Comtex News Network. Wollman holds an MBA and is a certified Public Accountant (inactive).